1. Pink Sheet

On A Roll? EU Could Follow US, China & Japan In Approving Remimazolam

 
• By Neena Brizmohun

Paion’s novel sedation drug, remimazolam, was approved in the US, China, and Japan this year and now the European Medicines Agency is set to decide whether it should be authorized for use across the EU.

Four darts arrows hitting in the target center dartboard. Success business goal concept
EU approval would mark the fourth major market in which remimazolam is approved • Source: Shutterstock

Paion is set to learn this week whether the European Medicines Agency will recommend pan-EU marketing approval for remimazolam, its ultra-short-acting intravenous benzodiazepine for use in procedural sedation. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography